Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20460439 | 1.00 | HPGD (0.80) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL13536268 | 1.00 | HPGD (0.80) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL12354846 | 1.00 | HPGD (0.80) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL1753628 | 0.98 | HPGD (0.76) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL10192065 | 0.94 | ALDH1A1 (0.71) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4557193 | 0.90 | ALDH1A1 (0.84) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL10726712 | 0.90 | ALDH1A1 (0.84) | HPGDALDH1A1KMT2AMEN1PKM | |
| SCHEMBL7132525 | 0.89 | HPGD (1.00) | HPGDALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL27479149 | 0.89 | HPGD (1.00) | HPGDALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL10721733 | 0.87 | HPGD (0.95) | HPGDALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| CN-112592310-B | 2-hydroxypyridine compound and synthetic method thereof | 南京工业大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021121420-A1 | BENZOPYRAZOLE COMPOUND AND INTERMEDIATE, PREPARATION METHOD, AND APPLICATION THEREOF | 江苏凯迪恩医药科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-112592310-A | 2-hydroxypyridine compound and synthetic method thereof | 南京工业大学 | 2021-04-02 | — | — | CN | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| WO-2017214005-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20080015190-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| CN-1097053-C | 1,2,3, 4-tetrahydro-benzofuro [3,2, -c ] pyridine derivatives, preparation method and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2002-12-25 | — | — | CN | disclosed |
| CN-1237179-A | 1,2,3,4-tetrahydro-benzofuro [3,2-c] pyridine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1999-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HPGD 140/4885ALDH1A1 433/4885KMT2A 1610/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HPGD 477/4885ALDH1A1 3756/4885KMT2A 423/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | HPGD 140/4885ALDH1A1 433/4885KMT2A 1610/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | HPGD 1041/4885ALDH1A1 1270/4885KMT2A 3224/4885 |
| US-20080015190-A1 | Inhibitors of Histone Deacetylase | HDAC5, HDAC1, HDAC4 | HPGD 166/4885ALDH1A1 266/4885KMT2A 55/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | HPGD 2802/4885ALDH1A1 315/4885KMT2A 3483/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | HPGD 592/4885ALDH1A1 310/4885KMT2A 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.